Aurinia Pharmaceuticals Launches New Lupus Nephritis Disease Awareness Program
February 14 2018 - 8:00AM
Business Wire
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP) (“Aurinia” or
the “Company”), a clinical stage biopharmaceutical company focused
on the global immunology market, today announced that it has
launched ALL INTM, an educational program for people living with
lupus nephritis (LN). ALL IN is designed to raise awareness for LN
and to support members of the LN community.
LN in an inflammation of the kidney caused by Systemic Lupus
Erythematosus (SLE) and represents a serious progression of SLE.
Though approximately three out of every five people with lupus will
go on to develop LN, many people living with lupus are less
familiar with LN and have a number of questions about how to manage
their disease once it affects the kidneys.
“As the leader of a national patient-led organization, I commend
Aurinia for having the vision to elevate awareness for lupus
nephritis, one of many potential manifestations of SLE that is
often misunderstood by those affected. Aurinia’s dedication to
educate and empower individuals and loved ones impacted by lupus
nephritis by providing essential information, resources and
support, is commensurate with our mission to improve quality of
life,” stated Kathleen A. Arntsen, President and CEO, Lupus and
Allied Diseases Association.
ALLINforLupusNephritis.com, the first component of the ALL IN
program, is a website that features educational information about
LN, downloadable resources, helpful links, and personal stories and
insights shared by people affected by LN. Visitors to the ALL IN
website also have the opportunity to receive ongoing news and
updates.
“We are committed to serving the needs of people with LN and
their families, and upon receiving extensive feedback from members
of the community, we conceptualized and built the ALL IN program—a
centralized place where those affected by LN can access pertinent
and timely information related to their condition,” said Brad
Dickerson, General Manager, Americas.
About Lupus Nephritis (LN)LN is an inflammation of the
kidney caused by Systemic Lupus Erythematosus (SLE) and represents
a serious progression of SLE. SLE is a chronic, complex and often
disabling disorder and affects more than 500,000 people in the
United States (mostly women). The disease is highly heterogeneous,
affecting a wide range of organs & tissue systems. It is
estimated that as many as 60 percent of all SLE patients will
develop clinical LN requiring treatment. Unlike SLE, LN has
straightforward disease outcomes (measuring proteinuria) where an
early response correlates with long-term outcomes. In patients with
LN, renal damage results in proteinuria and/or hematuria and a
decrease in renal function as evidenced by reduced estimated
glomerular filtration rate (eGFR), and increased serum creatinine
levels. LN is debilitating and costly and if poorly controlled, LN
can lead to permanent and irreversible tissue damage within the
kidney, resulting in end-stage renal disease (ESRD), thus making LN
a serious and potentially life-threatening condition.
About AuriniaAurinia is a clinical stage
biopharmaceutical company focused on developing and commercializing
therapies to treat targeted patient populations that are suffering
from serious diseases with a high unmet medical need. The company
is currently developing an investigational drug, for the treatment
of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS),
minimal change disease MCD and dry eye syndrome (DES). The company
is headquartered in Victoria, BC and focuses its development
efforts globally. For further information, see our website at
www.auriniapharma.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180214005223/en/
Aurinia PharmaceuticalsInvestor Contact:Celia
EconomidesVP, Corporate & Public
Affairsceconomides@auriniapharma.comorMedia
Contact:Christopher Hippolyte,
212-364-0458Christopher.hippolyte@inventivhealth.com
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From Apr 2024 to May 2024
Aurinia Pharmaceuticals (NASDAQ:AUPH)
Historical Stock Chart
From May 2023 to May 2024